Evotec AG (OTC:EVOTF)(OTCPK:EVTCY) and Merck KGaA's (OTCPK:MKGAF)(OTCPK:MKGAY) life sciences unit ink a set of collaboration agreements with the aim of discovering new therapeutic targets. The partnership will leverage Merck's comprehensive lineup of genetic reagents, including CRISPR and shRNA libraries, and Evotec's versatile screening platforms and disease expertise.
Evotec COO Dr. Mario Polywka says, "Together with our recent licensing of the CRISPR/Cas9 gene editing technology, these agreements with Merck further strengthen Evotec's offering in the area of target identification and validation for our partners. Deploying Merck's assay-ready reagents on our cellular screening platforms and in vivo models creates powerful capabilities in the area of target ID. With this we provide more value to joint clients by a one-stop-shop solution for this innovative drug discovery segment."
Financial terms are not disclosed.